Cyklokapron
By L. Kalesch. Concordia College, Moorhead Minnesota.
Reports are not usage guidelines cheap 500 mg cyklokapron mastercard treatment definition statistics, nor should they be read as an endorsement of or recommendation for any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Original Report: January 2005 Update 1: April 2006 Update 2: May 2008 Marian S. McDonagh, PharmD Kim Peterson, MS Susan Carson, MPH Rochelle Fu, PhD Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Copyright © 2010 by Oregon Health & Science University Portland, Oregon 97239. Final Report Update 3 Drug Effectiveness Review Project The medical literature relating to this topic is scanned periodically. Prior versions of this report can be accessed at the DERP website. Atypical antipsychotic drugs Page 2 of 230 Final Report Update 3 Drug Effectiveness Review Project STRUCTURED ABSTRACT Purpose Atypical antipsychotic agents are used to treat the symptoms of schizophrenia and bipolar disorder. The purpose of this review is to help policy makers and clinicians make informed choices about their use. Given the prominent role of drug therapy in psychiatric disease, our goal is to summarize comparative data on efficacy, effectiveness, tolerability, and safety. Ten atypical antipsychotics are currently available in the United States and Canada. Clozapine, the prototypic atypical antipsychotic, was introduced in 1989. Since then, 9 other atypical antipsychotics have been brought to market: risperidone (1993), risperidone long-acting injection (2003), olanzapine (1996), quetiapine (1997), ziprasidone (2001), aripiprazole (2002), extended-release paliperidone (2006), asenapine (2009), iloperidone (2009), and paliperidone long-acting injection (2009). Data Sources To identify relevant citations, we searched the Cochrane Central Register of Controlled Trials th (1st Quarter 2010), Cochrane Database of Systematic Reviews (4 quarter 2009), MEDLINE (1950 to week 4 January 2010), and PsycINFO (1806 to February week 1 2010) using terms for included drugs, indications, and study designs. We attempted to identify additional studies through searches of reference lists of included studies and reviews. We also searched the US Food and Drug Administration Center for Drug Evaluation and Research website for medical and statistical reviews of individual drug products. Finally, we requested dossiers of published and unpublished information from the relevant pharmaceutical companies for this review. Review Methods Study selection, data abstraction, validity assessment, grading the strength of the evidence, and data synthesis were all carried out according to our standard review methods. Results Schizophrenia and Related Psychoses In patients with schizophrenia, while differences in short-term efficacy are not apparent among the atypical antipsychotics, clozapine and olanzapine have been found to result in lower rates of discontinuation of drug over periods of up to 2 years. Clozapine has reduced suicides and suicidal behavior in patients at high risk, but results in more discontinuations due to adverse events than the others. While risperidone and extended-release paliperidone resulted in higher rates of extrapyramidal symptoms in some studies, the majority of studies find no differences among the drugs. Risperidone was found to result in more frequent or more severe sexual dysfunction symptoms than quetiapine, but was similar to extended-release paliperidone or ziprasidone. Very limited evidence existed regarding atypical antipsychotics used for the treatment of schizophrenia in subgroup populations. Among adolescents with schizophrenia, quetiapine was not superior to placebo based on response rate, but was superior based on improvements Atypical antipsychotic drugs Page 3 of 230 Final Report Update 3 Drug Effectiveness Review Project measured by the Positive and Negative Syndrome Scale. Differences by race were not found, but women had greater improvements with clozapine on a global impression scale, and with olanzapine on a quality of life scale compared with men. Bipolar Disorder In adults with bipolar disorder, no significant differences were found between risperidone and olanzapine or asenapine and olanzapine in quality of life, remission, and response outcomes. Olanzapine resulted in greater mean weight gain compared with asenapine and risperidone, respectively, whereas asenapine resulted in a significantly higher rate of discontinuations due to adverse events than olanzapine. Otherwise, there were no significant differences between risperidone and olanzapine or between asenapine and olanzapine in extrapyramidal symptoms or between risperidone and olanzapine in discontinuations due to adverse events. In children and adolescents with bipolar disorder evidence is extremely limited; olanzapine and risperidone had similar response rates after 8 weeks of treatment and no significant differences in mean weight gain were found.
New York Heart Association functional class improved with both losartan and captopril (P≤0 buy generic cyklokapron 500mg online treatment 247. Hospital admissions for any reason were lower with losartan than captopril (P=0. Quality of life as measured with the DRIs, AIIRAs, and ACE-Is Page 24 of 144 Final Report Drug Effectiveness Review Project Sickness Impact Profile and the Minnesota Living with Heart Failure Questionnaire improved in 40 both treatment groups, with no significant difference between groups. As ELITE was not powered for the outcome of survival benefit, Pitt and colleagues 34 explored the unexpected finding of survival benefit in elderly heart failure patients in ELITE 14 with a second study, ELITE II. In this latter study, the goal was to examine the potential superiority of losartan over captopril for survival and tolerability. Inclusion criteria in ELITE II were similar to those of ELITE. The study population (N=3152) also had symptomatic heart failure, but follow-up was somewhat longer (median 1. For the primary endpoint of all- cause mortality, deaths with losartan (15. The secondary endpoint, a composite of sudden death or resuscitated arrest, also did not differ significantly between treatment groups (captopril 7. Health-related quality of life (measured with the Euroqual-5D) did not change significantly from baseline in either treatment group due to the large effect of nonsurvivors on this outcome (who had a score of 0 at the time of death). Among survivors, however, quality of life improved significantly overall for both groups (P<0. The third trial, OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin 27 II Antagonist Losartan), was also a large (N=5477), multi-center, international, double-blind randomized controlled trial, which aimed to examine both the noninferiority of losartan to captopril as well as the superiority of losartan. The inclusion criteria were somewhat different from ELITE II: patients 50 years of age and older with an acute myocardial infarction, with either heart failure, decreased ejection fraction, evidence of acute or old Q-wave, or anterior myocardial infarction. For the primary outcome of all-cause mortality, there was no statistically significant difference between losartan (18%) and captopril (16%) (relative risk, 1. The only exception was cardiovascular death, which was more common with losartan (15. In ELITE II total withdrawals (P value not reported) and withdrawals due to adverse events (P<0. In the OPTIMAAL, discontinuation of study drug for any reason was much higher with captopril (23%) than with losartan (17%) (relative risk, 0. Discontinuation due to adverse events was also less with losartan (P<0. Harms 34 In ELITE, persisting increase in serum potassium and hypotension were not significantly different between treatment groups (P>0. In ELITE II rates of worsening heart failure were similar between groups (25% both groups). Other adverse events were not reported for this trial. Hypotension and congestive heart failure were not significantly different between groups. Subgroup analyses 34 In ELITE the decrease in mortality with losartan was generally consistent across different subgroups, including age, ejection fraction, and New York Heart Association functional class. The exception was a similar mortality in women (9/118 with losartan compared with 8/122 with 34 captopril; P value not reported). Among patients on prior beta-blocker therapy, however, more events occurred with losartan than with captopril for the composite outcomes of all-cause mortality and hospital admissions (P=0. There was no interaction between treatment and beta-blocker subgroups for the primary outcome of all-cause mortality (P>0. Event rates were higher for both losartan and captopril in patients not on beta-blockers. Losartan compared with enalapril (monotherapy and combination therapy) (n=5) 26, Five small trials compared losartan with enalapril, all in populations with stable heart failure. Several of these studies involved patients stabilized on an 26, 32 29, 30, 35 ACE-I, while others included only subjects with no recent use of ACE-Is or AIIRAs. The largest of the 5 trials included only 166 26 26, 32, 35 patients. The 3 parallel-group studies were all of monotherapy, while 1 cross-over 30 study (N=20) included a placebo, monotherapy with either losartan or enalapril, and a combination group.
Pregnancy morbidity (a) One or more unexplained deaths of a morphologically normal agulability is unlikely to be the sole mechanism by which thrombo- fetus at or beyond the 10th week of gestation purchase cyklokapron 500mg free shipping medications that cause hyponatremia, with normal fetal philia, either acquired or inherited, increases the risk for pregnancy morphology documented by ultrasound or by direct examination failure or defective placentation. However, most associations are modest hormonal abnormalities and paternal and maternal chromosomal in strength and vary with type of thrombophilia and type of causes excluded. Lupus anticoagulant present in plasma, on two or more occasions at types of antiphospholipid antibodies and placenta-mediated preg- least 12 weeks apart, or nancy complications were found to be inconsistent in a recent large 2. Anticardiolipin antibody of IgG and/or IgM isotype in serum or systematic review. The investigators concluded that it is weeks apart, or questionable whether a diagnosis of APS in the setting of pregnancy 3. Anti-beta2 glycoprotein I antibody of IgG and/or IgM isotype in th complications should be established if only these antibodies are serum or plasma (in titer the 99 percentile), present on two or more occasions, at least 12 weeks apart. Further- more, the most recent and larger prospective cohort studies found AdaptedfromMiyakis,2006. It is attractive to hypothesize that hypercoagulability with associations. However, coagulation and inflammation are closely related pathways and several observations have implicated a role for Clinical trial evidence of effect of aspirin or heparin on both procoagulant and inflammatory pathways in pregnancy failure. Associations between pregnancy complications and several forms of thrombophilia OR (95% CI) Miscarriage Recurrent 1st Single 2nd Pregnancy loss (1st or 2nd trimester trimester Stillbirth (3rd Late (2ndor 3rd (regardless of Preeclampsia Preeclampsia Type of thrombophilia trimester) miscarriage miscarriage trimester loss) trimester loss) gestational age) (mild or severe) (severe) Anticardiolipinantibodies 3. Terminology of pregnancy loss at various gestational ages may vary among included studies. No Interpretation of the current clinical trial evidence is provided here. A very recent General considerations systemic review observed clinically important and statistically First, depending on the type of pregnancy complications, the natural significant reductions in several important outcomes, but the history of subsequent pregnancies without pharmacological interven- investigators stated that their confidence was tempered by potential tion is often uncertain. For example, recurrence rates of preeclamp- small-study effects and observed modest effects on outcomes in the 2 largest trials. The nancy loss, the prognosis of a subsequent live birth ranges from 0% investigators did not observe different effects in trials in which to 99%, indicating the difficulty in drawing conclusions. The American populations varied and the onset of follow-up differed per study. College of Chest Physicians (ACCP) 2012 guidelines give a grade Live birth rates in women recruited in very early pregnancy 1B recommendation to treat women considered at risk for preeclamp- generally were substantially lower than in women who were sia with aspirin throughout pregnancy, starting from the second trimester, over no treatment. Therefore, aspirin should be offered on an Second, beneficial effects of antithrombotic agents have been individualized basis and decisions made on the basis of the woman’s suggested by results from observational studies that have intrinsic risk profile from her obstetric and medical history. For women with methodological issues undermining their validity to assess efficacy a history of severe preeclampsia in the context of APS, I offer of an intervention. Whether women who have a diagnosis of APS based on venous Third, although clinical trials have been performed in recent years, thromboembolism only should be considered at high risk for preeclampsia is basically unknown. Contrary to other views,25 in my these are generally limited by small sample sizes and often lacked a control arm without active intervention. Furthermore, study popula- opinion, there is no evidence that aspirin on top of regular tions vary widely. Some trials used very stringent inclusion criteria antepartum thrombosis prophylaxis with LMWH improves preg- that limit the generalizability of the findings to women with other or nancy outcome in women with APS without a history of pregnancy coexisting complications. Other trials used very broad inclusion complications. Women with a history of preeclampsia, with or criteria that make it difficult to draw conclusions for subgroups with without inherited thrombophilia, are also being counseled regarding specific pregnancy complications or thrombophilia. Some meta- the small reduction in risk of recurrence in a next pregnancy and analyses purposely pooled effects of heterogeneous interventions in prescribed aspirin on an individualized basis. It should be realized that the summary effects from such analyses do not have the same scientific Heparin, with or without aspirin, to prevent pregnancy loss strength as a randomized controlled trial of sufficient size. The efficacy of antithrombotic agents in women with unexplained (eg, in the absence of abnormal parental karyotype, uterine anoma- lies, or APS) recurrent pregnancy loss was compared with no Summary of randomized controlled trials and 26,27 treatment or placebo in 2 relatively large randomized trials. In meta-analyses the SPIN study, 294 women with 2 or more unexplained pregnancy Aspirin to prevent pregnancy loss losses were randomized to enoxaparin 40 mg combined with aspirin In women with APS, almost no data are available to support the use 75 mg plus standard surveillance or standard surveillance only.
There were 2 cases of herpes simplex dermatitis observed with pimecrolimus cheap cyklokapron 500 mg visa medicine definition, of which 1 case was considered to be study medication 45 related. A case of Kaposi’s varicelliform eruption together with a bacterial skin infection (possibly related) in 1 patient on tacrolimus 48 0. Topical calcineurin inhibitors Page 35 of 74 Final Report Drug Effectiveness Review Project Table 11. Number of cases collected from 17 trials (N=7761) that reported serious viral infections Vehicle-controlled Active-control (n=3461) (n=4300) Topical Tacro Pime Vehicle Tacro Pime steroids Herpes simplex virus 24 15 13 20 18 40 Molluscum contagiosum 8 3 1 NR 0 2 Eczema herpeticum 5 3 4 0 2 0 Herpes zoster 7 NR 0 NR 1 2 Abbreviations: NR, not reported; pime, pimecrolimus; tacro, tacrolimus. A retrospective cohort study in 388 Japanese patients suggested that there may be little difference between topical tacrolimus and topical steroids in the incidence of herpes simplex infection or eczema herpeticum of the face or neck. However, the duration of topical steroid and topical tacrolimus exposure was significantly different between the groups. Patients were exposed to 1 to 3 years of tacrolimus 0. In an open-label, single-arm study of 799 adults and children, the reported rates of herpes simplex (6. Interpretation of the results should be considered with some caution since about 50% of patient data on adverse events were not available for inclusion. Of the 50% who withdrew from the open-label study, 37% withdrew because of noncompliance, patient withdrawal, and loss to follow-up. Are there other subgroups of patients based on demographics (for example, age, racial groups, gender) and comorbidities (for example, immunodeficiencies) for which either pimecrolimus or tacrolimus is more effective or associated with fewer adverse events? Summary There is insufficient comparative evidence in subgroup populations based on age, gender, race, and comorbidities for tacrolimus and pimecrolimus. Most subgroup analyses were performed for either tacrolimus or pimecrolimus in vehicle-controlled trials. Topical calcineurin inhibitors Page 36 of 74 Final Report Drug Effectiveness Review Project Detailed Assessment None of the head-to-head studies conducted subgroup analyses. Subgroup analyses conducted in all the placebo trials were done post hoc. We did not find any good-or fair-quality studies evaluating the use of topical calcineurin inhibitors in patients with eyelid dermatitis. Age In 1 pimecrolimus trial, infants 3 months to 1 year of age exhibited larger treatment effect in the proportion of patients with IGA score ≤1 than those who were 1 to 2 years of age (65. Ethnic origin One post hoc analysis suggests that black adults (N=110) had better response in achieving >90% improvement of disease with tacrolimus 0. One post hoc analysis (N=589) showed no difference between white and multiracial patients in their response to pimecrolimus 1% cream (vehicle-corrected value in percent patients 62 with IGA score ≤1: white 21. Baseline disease severity Patients with mild disease who were randomized to tacrolimus 0. In 241 patients with severe disease, treatment with tacrolimus 0. The success rate (>90% improvement based on PGE) was 35. One study showed little difference in the treatment effect of pimecrolimus 1% cream in patients with mild and moderate disease compared with patients with severe disease (estimated 25 between-group difference in % change in EASI score: 4. Body surface area involved with atopic dermatitis In a small subset of adults with >75% body surface area affected by atopic dermatitis (N=82), patients receiving tacrolimus 0. Chronic hand dermatitis Overall, the use of pimecrolimus 1% cream 2 times a day plus vinyl glove dressing in adults with chronic hand dermatitis was more effective than vehicle in achieving an IGA score ≤1 at 3 56 weeks. Topical calcineurin inhibitors Page 37 of 74 Final Report Drug Effectiveness Review Project Assumptions and Limitations Pooling across populations and stratifying by disease severity Based on epidemiologic studies and the natural history of the disease, we assumed that adult patients included in our review did not have drastically different disease (were not treatment resistant) when compared with infants and children, such that data could not be pooled. In all trials, information regarding treatment resistance or duration of illness in adults was not specified at baseline. Therefore, we assumed no significant differences in the populations and stratified the results by disease severity prior to analyses.
